Recent studies indicate that oncogenes may be involved in determining the sensitivity of human cancers to chemotherapeutic agents. To de®ne the eect of HER-2/neu oncogene overexpression on sensitivity to chemotherapeutic drugs, a full-length, human HER-2/neu cDNA was introduced into human breast and ovarian cancer cells. In vitro dose-response curves following exposure to 7 dierent classes of chemotherapeutic agents were compared for HER-2-and control-transfected cells. Chemosensitivity was also tested in vivo for HER-2-and control-transfected human breast and ovarian cancer xenografts in athymic mice. These studies indicate that HER-2/neu overexpression was not sucient to induce intrinsic, pleomorphic drug resistance. Furthermore, changes in chemosensitivity pro®les resulting from HER-2/neu transfection observed in vitro were cell line speci®c. In vivo, HER-2/neu-overexpressing breast and ovarian cancer xenografts were responsive to dierent classes of chemotherapeutic drugs compared to control-treated xenografts with no statistically signi®cant dierences between HER-2/neu-overexpressing and nonoverexpressing xenografts. We found no instance in which HER-2/neu-overexpressing xenografts were rendered more sensitive to chemotherapeutic drugs in vivo. HER-2/neu-overexpressing xenografts consistently exhibited more rapid regrowth than control xenografts following initial response to chemotherapy suggesting that a high rate of tumor cell proliferation rather than intrinsic drug resistance may be responsible for the adverse prognosis associated with HER-2/neu overexpression in human cancers.
Introduction
The human HER-2/neu (c-erbB-2) proto-oncogene encodes a 185 kD transmembrane receptor tyrosine kinase which is homologous to, but distinct from, the epidermal growth factor receptor (EGFR) as well as other members of the type I receptor tyrosine kinase family (i.e. . Sequence identity between members of this receptor family in their extracellular, and intracellular tyrosine kinase domains is 40 ± 60% and 60 ± 80%, respectively (Rajkumar and Gullick, 1994) . Ampli®cation of the HER-2/neu gene occurs in *25 ± 30% of human breast and ovarian cancers resulting in overexpression of the gene product, and this molecular alteration, when present, is an independent predictor of both relapse-free and overall survival in these diseases (Pauletti et al., 1996; Slamon et al., 1987) . In breast cancer, overexpression of the HER-2/neu gene has been associated with a number of other adverse prognostic factors including: advanced pathologic stage (Seshadri et al., 1993) , number of axillary lymph node metastasis (Slamon et al., 1987) , absence of estrogen and progesterone receptors (Quenel et al., 1995; Querzoli et al., 1990; Barbareschi et al., 1992) , increased S-phase fraction (Borg et al., 1991; Anbazhagan et al., 1991) , DNA ploidy (Stal et al., 1994; Lee et al., 1992) , and high nuclear grade (Berger et al., 1988; Poller et al., 1991) . A role for the HER-2/ neu alteration in metastasis has also been suggested given the increased occurrence of visceral metastasis (Kallioniema et al., 1991) and higher incidence of micrometastatic bone marrow disease (Pantel et al., 1993) in patients with HER-2/neu overexpression. In addition, expression of HER-2/neu has prognostic signi®cance in patients with gastric (Yonemura et al., 1991) , endometrial (Berchuck et al., 1991; Hetzel et al., 1992; Lukes et al., 1994; Saari et al., 1995) , and salivary gland cancers (Semba et al., 1985; Press et al., 1994) . The exact role alteration of HER-2/neu receptor expression plays in the pathogenesis of these cancers remains unclear.
Retrospective data from two large clinical trials in breast cancer suggests an association between HER-2/ neu overexpression and resistance to chemotherapy. Results from the Intergroup Study 0011 (Allred et al., 1992) and the International (Ludwig) Breast Cancer Study Group (Gusterson et al., 1992) led investigators to conclude that node-negative breast cancer patients whose tumors contain HER-2/neu overexpression have a less favorable prognosis due to a lack of response to adjuvant cyclophosphamide (CPA), methotrexate (MTX), and 5-¯uorouracil (5-FU)-based chemotherapy (CMF). In addition, in a study of 68 patients with advanced breast cancer, Wright and colleagues reported a shortened survival for patients with HER-2/neu overexpression who were treated with mitoxantrone despite the fact that response rates between HER-2/neu-overexpressing and non-overexpressing tumors were similar, 50% vs 58%, respectively (Wright et al., 1992) . A study of HER-2/neu overexpression in epithelial ovarian cancer demonstrated that patients whose tumors had the alteration were more likely to fail chemotherapy with CPA and carboplatin (CBDCA) (Felip et al., 1995) . Conversely, in a clinical series reviewed by Klijn et al. patients with metastatic breast cancer and ampli®cation of the HER-2/neu gene had a superior response to CMF chemotherapy (75%) compared to patients without HER-2/neu ampli®ed tumors (45%) and the median length of progression-free survival from the start of chemotherapy was superior in patients whose tumors exhibited ampli®cation (Berns et al., 1995; Klijn et al., 1993) . Recently, data from the Cancer and Leukemia Group-B demonstrated that node-positive breast cancer patients with HER-2/neu overexpression derived a bene®t from doxorubicin (DOX)-based adjuvant chemotherapy which is dose-dependent indicating that HER-2/neu overexpression may be associated with an increased response to DOX (Muss et al., 1994) . In composite, the clinical data to date are somewhat contradictory and do not adequately de®ne what role, if any, HER-2/neu overexpression plays in chemotherapy response. Moreover, there is little experimental data to address this potentially important question. In one study evaluating in vitro chemosensitivity in HER-2/neu-transfected MCF7 breast carcinoma cells, no signi®cant dierence in response to either 5-FU or DOX was seen, while HER-2 overexpression was associated with a 2 ± 4-fold increase in resistance to cisplatin (CDDP) (Benz et al., 1992) . In another study, HER-2/neu transfection of MDA-MB-435 cells conferred resistance to paclitaxel (TAX) via an mdr-1-independent mechanism (Yu et al., 1996) . In vitro studies of lung cancer cell lines demonstrated an association between HER-2/neu expression levels and intrinsic chemoresistance to six dierent chemotherapeutic drugs (Tsai et al., 1993) , and transfection of HER-2/neu cDNA into one lung cancer cell line resulted in an increase in drug resistance (Tsai et al., 1995) .
In an attempt to further de®ne the eect of HER-2/ neu overexpression on sensitivity to chemotherapeutic drugs in human breast and ovarian cancers, we introduced a full-length, human HER-2/neu cDNA, via a retroviral expression vector, into four dierent breast cancer cell lines: MCF7, MDA-MB-231, MDA-MB-435 and BT-20, and two dierent ovarian carcinoma cell lines: 2008 and Caov-3. All of the parental cell lines used for this study contain a single copy of the HER-2/neu gene and express basal levels of the gene product while the matched HER-2/neu retroviral transfectants overexpress the gene. Doseresponse curves using seven dierent classes of chemotherapeutic agents were constructed for the HER-2/neu-overexpressing cell lines as well as their mock-transfected parental controls. The rationale for this experimental approach was to allow direct comparison of genetically identical parent/daughter cells which dier only in that one member of the pair overexpresses the human HER-2/neu gene. This approach was taken to circumvent the diculty of comparing cell lines derived from separate sources which may inherently dier in characteristics other than HER-2/neu overexpression which could impact on drug sensitivity. The rationale for evaluating more than one cell line representing each of these two human malignancies is to avoid the possibility that any given observation could be unique to an individual cell line rather than being representative of a more generic biologic eect associated with HER-2/neu overexpression. Finally, to avoid the possibility that any observed eects might be restricted to an in vitro setting and because monolayer cell culture assays may not detect important multicellular mechanisms of drug resistance (Kerbel et al., 1994; Kerbel, 1995) , chemosensitivity was tested in vivo for breast and ovarian cancer parent/ daughter xenografts in an athymic mouse model.
Results
Characterization of human breast and ovarian cancer cells engineered to overexpress the HER-2/neu gene A full-length HER-2/neu cDNA was introduced via retroviral vector into a panel of human breast and ovarian carcinoma cells which are known to have a single copy of the HER-2/neu gene and to express normal' levels of the gene product. Breast cell lines BT-20 and MDA-MB-435 were established from previously untreated patients making them less likely to have treatment-induced chemotherapeutic drug resistance while the MCF7 cell line was established from a patient with prior radiation and hormonal therapy and the MDA-MB-231 cell line was derived from a patient previously treated with multidrug chemotherapy (5-FU, CPA, DOX, MTX, and prednisone). The ovarian carcinoma cell line 2008 was established from a patient who had not had prior chemotherapy, whereas the Caov-3 cell line was derived from a patient whose tumor had been exposed to prior 5-FU, DOX, and CPA in vivo. This spectrum of cell lines allows for response data representative of a diverse group of human breast and ovarian cancers. HER-2/neuengineered and control cells were identically infected using a neomycin phosphotransferase-based vector which either contained, or did not contain, a fulllength HER-2/neu cDNA. Retroviral infectants were selected for neomycin resistance and subjected tō uorescence activated cell sorting (FACS) analysis for detection of the p185 HER-2 protein. Western blot analysis con®rmed a marked increase in p185 HER-2 expression in cells engineered to overexpress the gene relative to mock (NEO)-infected controls (Figure 1a and b) . SK-BR-3 human breast carcinoma cells and SK-OV-3 human ovarian carcinoma cells naturally overexpress the HER-2 receptor and were included in these studies for comparison of non-manipulated overexpressing , the phosphorylation state of p185 HER-2 was assessed using immunoblotting techniques. Protein lysates from each of the transfected cell lines were subjected to immunoprecipitation with a p185 HER-2 speci®c monoclonal antibody. These experiments were performed on cell lines both with and without prior exposure to heregulin B-1, a growth factor ligand cloned on the basis of its ability to induce tyrosine phosphorylation of p185 through the formation of HER-2/HER-3 and/or HER-2/HER-4 heterodimeric complexes (Sliwkowski et al., 1994; Plowman et al., 1993) . The resulting immunoprecipitates were then resolved by polyacrylamide gel electrophoresis (SDS ± PAGE) and probed with an anti-phosphotyrosine antibody (Figures 2a and 3a) . These results indicate that HER-2/neu cDNA transfection results in expression of a p185 HER-2 protein which is either constitutively tyrosine phosphorylated or can be phosphorylated on exposure to heregulin B-1 in each of the breast cell lines with the exception of MDA-MB-231 (Figure 2a 3 molecules/cell, relative to HER-2 or HER-3 in this panel of cell lines, therefore heregulininduced HER-2 phosphorylation appears to be predominantly in¯uenced by the abundance of HER-2/HER-3 heterodimers in these cells. Having successfully engineered the breast and ovarian cells to overexpress p185 , we next evaluated the eects of overexpression on their sensitivity to chemotherapeutic drugs in vitro and in vivo.
Eect of HER-2/neu overexpression on sensitivity of human breast and ovarian cells to chemotherapeutic agents in vitro
The eects of HER-2/neu overexpression in human breast and ovarian carcinoma cell lines on sensitivity to a variety of chemotherapeutic agents was determined in vitro. The eective dose range for each drug (IC 10 ± IC 90 ) was identi®ed using a range of ten dierent doses, each tested in quintuplicate. To assure accuracy and reproducibility, all sets of in vitro assays were repeated at least two times. This assay yielded 4-parameter, sigmoidal curve ®ts with correlation coecients ranging from 0.938 ± 0.999. Dierences between dose-response curves were assessed using 2-factor analysis of variance (ANOVA) of data points which fell between the IC 20 and IC 80 . Representative data from these experiments Tables 1 and 2 . These data include the IC 50 +one standard deviation and the signi®cance level for dierences between control (NEO) and HER-2-engineered cell lines. Introduction of neomycin phosphotransferase gene via the NEO control vector and selection in neomycin resulted in no change in chemosensitivity in MCF7 cells (data not shown) indicating that neomycin resistance does not confer cross-resistance to chemotherapeutic agents in vitro.
Clinically achievable peak plasma levels of chemotherapeutic drugs from standard dosing schedules used in humans are shown for reference in Table 1 . HER-2/neu overexpression in MCF7 breast carcinoma cells resulted in a 2.5-fold decrease in sensitivity to the platinum analog CBDCA, as well as a twofold decrease in 5-FU sensitivity. Conversely, a twofold increase in sensitivity to TAX was noted while no change in sensitivity to the other four drugs tested was found (Table 1) . These results are similar to those reported by Benz et al. who noted a 2 ± 3-fold decrease in sensitivity to CDDP but no change in sensitivity to DOX or 5-FU in MCF7 cells which overexpress HER-2/neu (Benz et al., 1992) . In contrast, MDA-MB-231/HER-2 cells were rendered more sensitive to four of the seven drugs tested (Table 1 ). This increase in sensitivity ranged from 1.4-fold for thiotepa (TSPA) to 4100-fold for TAX. The BT-20/HER-2 cells were also 2 ± 4-fold more sensitive to TSPA and 5-FU, but like MCF7/HER-2 cells, they were more resistant to platinum compounds. Lastly, MDA-MB-435/HER-2 cells exhibited no change in chemosensitivity to any of the seven classes of chemotherapeutic agents tested. Among the ovarian carcinoma cell lines, Caov-3/HER-2 cells were slightly more sensitive to DOX and vinblastine (VBL) compared to Caov-3/NEO; however, HER-2/neu overexpression in 2008 cells resulted in a threefold and 7.5-fold increase in resistance to CBDCA and TSPA, respectively (Table 2 ).
These results indicate that HER-2/neu overexpression does not produce any consistent or predictable change in drug sensitivity pro®les in vitro across the various cell lines tested and underscore the necessity of evaluating more than one cell line prior to drawing general conclusions on the eect of this alteration on chemotherapeutic response in human cancer cells. Moreover, the dierences in chemosensitivity patterns among the HER-2/neu-transfected cell lines did not appear to correlate with basal or heregulin B-1-induced tyrosine phosphorylation of p185 . Despite the fact that chemosensitivity in HER-2/neu-overexpressing cells was cell line speci®c, some trends did emerge from the data. HER-2/neu-overexpression had no major eect on sensitivity to DOX in any of the six cell lines tested with the exception of Caov-3/HER-2 cells where it was associated with a small (0.5 mM to 0.3 mM) but statistically signi®cant increase in sensitivity. Similarly, HER-2/neu overexpression had minimal eects on response to etoposide (VP-16) with only one cell line, MDA-MB-231, exhibiting a slight increase in sensitivity after transfection with HER-2/neu. Increased resistance to platinum analogs was observed in three of the six cell lines with HER-2/neu overexpression compared to their controls. Finally, when agents which interfere with microtubule formation (VBL and TAX) were studied, three of six HER-2/neuoverexpressing cell lines demonstrated an increase in sensitivity.
Eect of HER-2/neu expression on chemosensitivity of breast and ovarian xenografts in vivo
To further evaluate and expand drug sensitivity studies associated with HER-2/neu overexpression, we developed an in vivo chemotherapeutic drug sensitivity assay which utilized serial measurements Table 1 Eect of HER-2/neu overexpression on sensitivity of human breast cells to chemotherapeutic agents in vitro (Gormley et al., 1979) 5.6 (Robert et al., 1982) 1000 (MacMillan et al., 1978) 940 (Wiernik et al., 1987) 10.6 (Cohen et al., 1986) 400 (Nelson et al., 1980) 50
1982) a , *, P<0.05; **, P<0.01; ***, P<0.001.
b CBDCA substituted for CDDP for MCF7/NEO and MCF7/HER-2. Peak plasma concentration of CBDCA is 50 mM (Harland et al., 1984) . Data shown are IC 50 values for each drug. Error is reported as +one standard deviation. The peak plasma levels of each drug achievable in humans with standard dosing schedules are shown for reference Table 2 Eect of HER-2/neu overexpression on sensitivity of human ovarian cells to chemotherapeutic agents in vitro (2008) carcinoma cells were selected for testing because of their predictable tumor formation in athymic mice. Immunohistochemical analysis of sections from these tumors and Western blot analysis from cell lines derived from these xenografts con®rmed that the relative expression level of HER-2/neu was maintained during the course of the study (data not shown). Overexpression of HER-2/neu in MCF7 breast carcinoma cells resulted in a signi®cant change in their in vivo growth characteristics (Figure 4) . By day 50, MCF7/HER-2 tumors were 2.7-fold larger than MCF7/NEO tumors (P=0.0001). At the onset of chemotherapy administration, animals were assigned to treatment groups such that initial tumor volumes were the same in each group (55+4 mm 3 ). Because the MCF7/NEO xenografts have a signi®cant dierence in inherent growth rate compared to MCF7/HER-2 xenografts, the ratio of chemotherapy-treated to untreated control tumor volume (T/C ratio) was calculated for each tumor. The maximum response to chemotherapy, de®ned as the point at which the T/C ratio was at a minimum, was determined for each individual tumor. The maximum drug responses for the MCF7/NEO xenografts were then directly compared to responses found in the MCF7/HER-2 xenografts.
In the human breast cancer xenograft model, all ®ve drugs tested resulted in signi®cant responses for both MCF7/NEO and MCF7/HER-2 tumors compared to their respective untreated control tumors (P50.05) indicating that HER-2/neu-transfected MCF7 xenografts maintain sensitivity to these chemotherapeutic drugs in vivo ( Figure 5 ). The mean time to point of maximum response was 17+5 days and was independent of the drug tested or tumor type (i.e. NEO vs HER-2). Tumor regrowth following day 21 uniformly occurred indicating a lack of prolonged response to the initial treatment. Of note was the fact that there was a signi®cant dierence in regrowth rates following responses to chemotherapy when comparing MCF7/NEO to MCF7/HER-2 tumors. The mean tumor doubling time following chemotherapy was 14.6 days for MCF7/HER-2 tumors compared to 23.8 days for MCF7/NEO tumors (P=0.0001). This demonstrates that HER-2/neu-overexpressing tumors maintain their proliferative advantage following exposure to chemotherapy in vivo. The T/C ratios at the point of maximum response are represented graphically by box plots (Figure 5 ). Treatment with DOX resulted in signi®cant responses for both MCF7/NEO and MCF7/HER-2 tumors compared to their respective untreated control groups (Figure 5a ). The dierence in the magnitude of maximum response to DOX between MCF7/NEO and MCF7/HER-2 tumors was not statistically signi®cant (P=0.13). Treatment with CDDP also resulted in signi®cant responses for both MCF7/ NEO and MCF7/HER-2 tumors and again mean CDDP-treated T/C ratios were not signi®cantly dierent at the point of maximum response ( Figure  5b, P=0.12) . Similarly, treatment with 5-FU resulted in signi®cant responses compared to controls for both MCF7/NEO and MCF7/HER-2 tumors ( Figure 5c) ; but the dierence in response between MCF7/NEO and MCF7/HER-2 was not statistically signi®cant (P=0.12). Treatment with TAX also resulted in signi®cant responses for MCF7/NEO and MCF7/ HER-2 tumors compared to vehicle-treated controls. Mean TAX-treated T/C ratios at maximum response were 0.19+0.09 and 0.30+0.18 for MCF7/NEO and MCF7/HER-2 tumors, respectively (Figure 5d ), and this dierence was marginally signi®cant (P=0.09). Finally, response to treatment with TSPA was signi®cant for both MCF7/NEO and MCF7/HER-2 tumors compared to control (Figure 5e ), but there was no signi®cant dierence between response of MCF7/ NEO xenografts compared to MCF7/HER-2 xenografts in response to TSPA (P=0.17). Additional analysis in a 2-factor ANOVA model failed to (Figure 6c ). Moreover, this result paralleled the in vitro results where a 7.5-fold increase in resistance to TSPA was noted in 2008 cells overexpressing HER-2/ neu. This dierence, however, appeared to be due to more rapid tumor regrowth for 2008/HER-2 xenografts following response to chemotherapy rather than intrinsic resistance to TSPA. In fact, at the time of maximal response to TSPA (day 10), there was no signi®cant dierence between 2008/NEO and 2008/ HER-2 xenografts (P=0.17). These data paralleled the results seen with MCF7/HER2 xenografts where rapid tumor regrowth occurred following response to chemotherapy in vivo.
Discussion
The involvement of some oncogenes in the development of chemotherapeutic drug resistance is suggested by experimental data demonstrating increased expression of c-fos, c-myc, and c-H-ras gene transcripts in cisplatin-resistant human ovarian carcinoma cells (Scanlon et al., 1989) . In transfection studies, c-myc expression was subsequently shown to result in an increase in resistance of Friend erythroleukemia cells to CDDP (Sklar and Prochownik, 1991) and the acquisition of a multidrug-resistant phenotype in NIH3T3 cells (Niimi et al., 1991) . Transfection of c-H-ras oncogene into NIH3T3 cells has also been shown to induce resistance to CDDP (Isonishi et al., 1991) and in one study both ras and trk-transformed NIH3T3 ®broblasts were less sensitive to CDDP and DOX compared to parental NIH3T3 cells (Peters et al., 1993) . More studies show an indirect relationship between oncogene expression and drug resistance. Introduction of v-H-ras or v-H-raf into rat hepatocytes results in increased expression of mdr-1 (Pglycoprotein) which is associated with multidrug resistance (Burt et al., 1988) . Marked increases in EGFR expression have been detected in several dierent cell types selected for resistance to naturalproduct anticancer drugs such as DOX, vincristine, and actinomycin-D (Meyers et al., 1986; Nuti et al., 1991; Dickstein et al., 1993) ; and increased resistance to DOX, VBL, CDDP and 5-FU has been reported in ZR75B human breast cancer cells transfected with EGFR (Dickstein et al., 1995) . In addition, ligands to and antibodies directed against EGFR have been shown to modulate sensitivity to chemotherapeutic drugs (Aboud-Pirak et al., 1988; Christen et al., 1990) , and`cross talk' between EGFR and P-glycoprotein is suggested by increases in P-glycoprotein phosphorylation in actinomycin-D-resistant Chinese hamster lung cells treated with epidermal growth factor (Meyers et al., 1993) .
Data from several clinical trials indicate a possible association between HER-2/neu overexpression and chemosensitivity, leading to speculation that overexpression of this proto-oncogene may also be relevant in predicting chemotherapeutic response. However, the potential role of HER-2 receptor overexpression in the development of chemotherapeutic drug resistance remains unclear for at least three reasons: (1) the con¯icting nature of the results published from the various clinical trials to date; (2) the paucity of experimental data describing the eects of HER-2/neu overexpression on drug sensitivity; and (3) the fact that studies done thus far using transfection strategies are restricted to single cell lines and/or do not address chemotherapeutic responses in vivo. Assessing the generic role of a given gene in the acquisition of chemotherapeutic drug resistance using typical transfection and selection strategies in a single cell line may be problematic due to inherent dierences in chemosensitivity of cell lines derived from dierent sources. In addition, following transfection and selection, individual subclones may possess varying degrees of sensitivity to chemotherapeutic agents which are random. Potential non-generic or cell line speci®c changes in chemosensitivity associated with HER-2/neu overexpression were avoided in the current studies by using multiple human cell lines to construct parent/ daughter pairs which dier only in their HER-2/neu expression level, circumventing the possibility that consistent observations across cell lines would be attributable to such eects. Moreover, two dierent epithelial cell types were analysed both in vitro and in vivo to signi®cantly decrease the chances that a consistently observed change might be due to phenomena unrelated to HER-2/neu overexpression but rather to a given epithelial type or assay method. We also sorted cells following transfection with HER-2/neu using FACS which results in collection of a pooled population (approximately 5610 5 ) of HER-2/ neu-overexpressing cells rather than individual subclones.
Using these approaches we found that HER-2/neu overexpression alone was not sucient to induce intrinsic, pleomorphic drug resistance in human breast or ovarian carcinoma cell lines and did not result in any consistent or predictable changes in chemosensitivity pro®les in an in vitro cell proliferation assay. The changes in chemosensitivity which were observed were cell line speci®c and not generic across the cell lines tested. This is illustrated by the fact that overexpression of the HER-2/neu receptor in MDA-MB-435 breast carcinoma cells had no eect on chemosensitivity to any of the seven dierent classes of drugs tested, whereas HER-2/neu-overexpressing MDA-MB-231 cells were rendered more sensitive to four of the seven drugs, and ovarian 2008 cells were rendered more resistant to two of the seven drugs tested. There are several potential reasons why HER-2/neu transfection results in alterations in chemosensitivity pro®les which are cell line dependent. First, a number of the cell lines used in this study were derived from tumors of patients who had prior exposure to chemotherapeutic agents and, as a result, may have already developed some degree of drug resistance. For example, Caov-3 cells are derived from a patient who had been exposed to combination chemotherapy and these cells are less sensitive to most of the drugs tested when compared to ovarian 2008 cells. Second, the eects of HER-2/neu transfection may be in¯uenced by other genetic alterations within a given cell line. Support for this hypothesis was demonstrated in co-transfection studies of both HER-2/neu and mutated c-H-ras in which induction of mdr-1 expression and resulting Pglycoprotein activity was observed only after cotransfection with both HER-2/neu and c-H-ras while neither gene alone resulted in a multidrug resistant phenotype (Sabbatini et al., 1994) . Third, the drug sensitivity pro®le of a given cell line following HER-2/ neu transfection and overexpression may depend on the cellular context in which HER-2/neu is overexpressed. For example, co-expression of other type 1 receptor tyrosine kinases within a cell may in¯uence HER-2/neu activity and subsequent intracellular signaling via formation of speci®c class 1 heterodimeric receptor species (Sliwkowski et al., 1994; Plowman et al., 1993) .
We were able to demonstrate dierences in basal and heregulin B-1-induced tyrosine phosphorylation of p185 HER-2 among the cell lines tested. To what degree co-expression of EGFR, HER-3, or HER-4 explain the dierences in heregulin B-1-induced tyrosine phosphorylation of p185 is the subject of ongoing investigations in our laboratory. It is clear from our results that some HER-2/neu-overexpressing cell lines exhibit shifts in drug sensitivity in vitro even in the absence of p185 HER-2 tyrosine phosphorylation (MDA-MB-231/HER-2 cells). Conversely, we found examples of cell lines which did exhibit heregulin B-1-induced tyrosine phosphorylation of p185 HER-2 and yet demonstrated no signi®cant shifts in chemosensitivity either in vitro (MDA-MB-435/HER-2) or in vivo (MCF7/HER-2). Our data on response of MDA-MB-435/HER-2 cells to TAX appears to dier from data reported previously (Yu et al., 1996) . Our data are derived from a pooled population of HER-2/neu-transfected MDA-MB-435 cells whereas the data reported by Yu et al. is based on analysis of three subclones of MDA-MB-435/ HER-2 cells. In addition, the shift in IC 50 noted by Yu et al. occurred at TAX concentrations in the millimolar range which is above the peak serum concentration achievable in humans, whereas we report the IC 50 of TAX on MDA-MB-435 cells to be 1.2 nanomolar. This apparent discrepancy may be explained by the dierent methodologies used to measure response to TAX ± clonogenic assays used in the previous study vs monolayer cell proliferation assays used in the current study. Finally, some of the in vitro changes in chemosensitivity observed in this study may not be clinically relevant as they occur at drug concentrations which are well above the peak plasma levels achievable in vivo. The HER-2/neu-overexpressing breast carcinoma cells MDA-MB-231 and BT-20 appear to be more sensitive to TSPA but the shift in dose-response occurs at a drug concentration 20-fold higher than levels routinely achievable in humans.
HER-2/neu transfection resulted in decreased in vitro sensitivity to platinum analogs in three of the six human tumor cell lines tested. This observation is of interest in light of recent studies which show that some anti-HER-2 antibodies are capable of increasing sensitivity to platinum through a mechanism involving a decrease in DNA repair activity (Hancock et al., 1991; Pietras et al., 1994; Arteaga et al., 1994) . Except for a slight increase in sensitivity observed in Caov-3/ HER-2 cells, HER-2/neu overexpression had no eect on sensitivity to DOX in any of the cell lines tested in vitro. Likewise HER-2/neu overexpression did not result in resistance to VP-16, TAX, or VBL which are known substrates for mdr-1 (Endicott and Ling, 1989) . Furthermore, HER-2/neu overexpression did not substantially aect sensitivity to VP-16 which targets topoisomerase II (Liu, 1989) . Topoisomerase II expression, however, has been found to be increased in *12% of breast carcinomas with HER-2/neu overexpression and may be due to co-ampli®cation of both genes owing to their close proximity on chromosome 17q (Smith et al., 1993) .
The shifts in dose-response curves secondary to HER-2/neu overexpression which were characterized in vitro did not result in parallel changes in chemosensitivity of the same cell lines in vivo. This is not surprising considering the limited capability of monolayer cell culture assays to recapitulate the complex microenvironment within a solid tumor in which physiologic, multicellular mechanisms of drug resistance are operative (Kobayashi et al., 1993; Casciari et al., 1994; Kerbel et al., 1994; Kerbel, 1995) . Furthermore, drug pharmacokinetics are markedly dierent in vivo compared to in vitro, and some degree of clonal selection may have unavoidably occurred in vivo causing dierences in chemotherapy response compared to the pooled HER-2/neu-transfected clones in vitro. Xenografts resulting from HER-2/neu-overexpressing cells did respond, relative to control, to all of the chemotherapeutic drugs tested except in cases where control cell lines were inherently resistant to drug treatment such as 2008 ovarian tumors treated with DOX or VP-16 which fail to respond regardless of the presence or absence of HER-2/neu overexpression. In addition, the magnitude of response in vivo was similar for ovarian 2008/HER-2 and 2008/NEO xenografts for CDDP, TAX, and TSPA, indicating that HER-2/neu overexpression in this cell line did not induce intrinsic chemotherapeutic resistance to these drugs in vivo. However, 2008/HER-2 tumors demonstrated more rapid recovery following response to TSPA compared to 2008/NEO tumors. MCF7/HER-2 breast xenografts responded, relative to untreated controls, to each of ®ve chemotherapeutic agents tested. The magnitude of response of MCF7/ HER-2 tumors varied from 19% to 37% less than MCF7/NEO tumors for the ®ve classes of cytotoxic drugs tested, suggesting the possibility of a slight increase in primary resistance to chemotherapy treatment in vivo for MCF7/HER-2 xenografts; however, this dierence was not statistically significant. We found no instance in which xenografts resulting from HER-2/neu-overexpressing cell lines were rendered more sensitive to chemotherapeutic drugs in vivo. Therefore, in this experimental model, HER-2/neu overexpression alone is insucient to confer increased sensitivity to DOX as has been hypothesized previously (Muss et al., 1994) . The MCF7 breast xenograft model, however, does demonstrate that HER-2/neu-transfected tumors are associated with a rapid rate of tumor regrowth following initial response to chemotherapy. Mean doubling time for tumor regrowth following response to chemotherapy was 14.6 days for MCF7/HER-2 tumors compared to 23.8 days for control-transfected tumors (P=0.0001). These data suggest that the apparent lack of response to chemotherapy among patients with HER-2/neu positive tumors seen in some clinical trials may be due to rapid tumor regrowth of surviving tumor cells following initial response to chemotherapy rather than intrinsic chemotherapeutic drug resistance at the time of chemotherapy treatment.
The drug response phenotype is not static within solid tumors. New drug-resistant variants may emerge during chemotherapy treatment due to selection of pre-existing, drug-resistant clones within a heterogeneous tumor cell population, or through adaptive selection of spontaneously arising drug-resistant clones during the life of a tumor. Our data indicate that HER-2/neu overexpression alone in human breast and ovarian cancer cells is not sucient to cause an intrinsic, pleotropic drug-resistant phenotype in vitro, nor does it signi®cantly impair or enhance response to initial chemotherapy treatment in vivo. However, the growth stimulus aorded by overexpression of p185 HER-2 allows for rapid proliferation of any surviving cells following treatment with chemotherapy. This may in turn allow the emergence of acquired chemotherapeutic drug resistance through the processes of clonal or adaptive selection of resistant tumor cells. Experiments designed to test the eects of HER-2/neu overexpression on acquired rather than intrinsic drug resistance are underway in our laboratory. If, as our experimental models suggest, the adverse prognosis seen in patients whose tumors have ampli®cation/overexpression of the HER-2/neu gene is due to rapid tumor cell proliferation rather than de novo resistance to chemotherapy, then maximizing reduction in tumor burden using more active agents and/or higher dose intensities may result in improved clinical response. This hypothesis is consistent with a recently published clinical trial (Muss et al., 1994) and may mean that assessment of HER-2/neu status in malignant breast tissue is important in selecting treatment regimens for patients.
Materials and methods

Cell lines and cell culture
Human breast carcinoma cell lines MCF7, BT-20, MDA-MB-231, MDA-MB-435, and SK-BR-3, and human ovarian carcinoma cell lines Caov-3 and SK-OV-3, were obtained from American Type Culture Collection (Rockville, MD). Human ovarian 2008 cells were established from a patient with serious cystadenocarcinoma of the ovary (DiSaia et al., 1972) . All cells were cultured in RPMI medium 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine and 1% penicillin Gstreptomycin-fungizone solution (Irvine Scienti®c, Santa Ana, CA).
Transfection and overexpression of the human HER-2/neu gene in human breast and ovarian carcinoma cells Human breast and ovarian carcinoma cells with normal levels of HER-2/neu expression were transfected with a full-length cDNA of the human HER-2/neu gene. Introduction of HER-2/neu into human cells was accomplished using the replication defective retroviral expression vector pLXSN into which the HER-2/neu cDNA was ligated (Chazin et al., 1992) . The same pLXSN vector devoid of HER-2/neu sequences but containing the neomycin phosphotransferase gene was packaged in an identical fashion and was used to infect control cells. Breast and ovarian carcinoma cells were infected as previously described (Pietras et al., 1994) . Stably transfected cell lines were selected according to level of HER-2/neu expression using FACS with indirect immuno¯uorescence labeling mediated by the murine monoclonal anti-HER-2/ neu antibody 4D5 (Genentech, Inc., South San Francisco, CA) and an anti-mouse IgG/FITC antibody (Caltag Laboratories, South San Francisco, CA). All cell lines were characterized for expression of HER-2/neu gene by Western blot analysis.
Western blot analysis
Cultured cells were washed in 137 mM NaCl solution containing 2.7 mM potassium chloride, 1.5 mM potassium phosphate and 8 mM sodium phosphate (Dulbecco's PBS, Gibco BRL, Gaithersburg, MD) and lysed at 48C in 20 mM Tris, pH 8.0; 137 mM NaCl; 1% Triton X-100; 10% glycerol; 5 mM EDTA; 1 mM sodium orthovanadate; 1 mM phenylmethyl-sulfonyl¯uoride; leupeptin 1 mg/ml and aprotinin 1 mg/ml. Insoluble material was cleared by centrifugation at 10 000 g for 10 min. Protein was quantitated using BCA (Pierce Biochemicals, Rockford, IL), resolved by SDS ± PAGE, and transferred to Immobilon-P (Millipore, Bedford, MA). The p185 HER-2 protein was detected by anti-c-neu (Oncogene Science, Uniondale, NY) using the ECL method (Amersham, Arlington Heights, IL).
Tyrosine phosphorylation of the HER-2/neu receptor HER-2/neu and mock-vector transfected breast and ovarian cell lines were examined for phosphorylation of p185 using SDS ± PAGE, as described previously (Pietras et al., 1995) . In brief, cells were cultured to 80% con¯uence in 100 mm dishes in RPMI media containing 10% FCS. The cells were washed 63 in PBS and then allowed to incubate in serum-free RPMI media for 24 h at 378C. Recombinant heregulin B-1 (kindly provided by Dr M Sliwkowski, Genentech, Inc., S. San Francisco, CA) 10 mM or control solution was added and allowed to incubate for 5 min at 378C. Cells were then washed in PBS and lysed using the conditions described above. Following protein quantitation, immunoprecipitations were performed by incubating 250 mg protein lysate with 5 mg/ml monoclonal anti-HER-2/neu antibody (Oncogene Science, Uniondale, NY) at 48C overnight with gentle agitation. Protein A-agarose (BioRad, Richmond, CA) was added to precipitate the antigen-antibody complex and the immunoprecipitates were washed three times in lysis buer prior to electrophoresis. Proteins were then transferred to Immobilon-P and immunoblotting was performed using monoclonal anti-phosphotyrosine antibody, PY20 (Santa Cruz Biotechnology, Santa Cruz, CA).
Cell proliferation assays
Aliquots of 5610 3 cells were plated in quintuplicate in 96-well microdilution plates. Following cell adherence, experimental media containing either speci®c chemotherapeutic agents or control media was added. Serial twofold dilutions were performed to span the eective dose range for each drug. Representative drugs from seven dierent classes of chemotherapeutic agents were tested including: anthracycline antibiotics ± DOX (Cetus Corporation, Emeryville, CA); antimetabolites ± 5-FU (Solo Park Laboratories, Inc., Elk Grove Village, IL); alkylating agents ± TSPA (Lederle Laboratories, Pearl River, NY); vinca alkaloids ± VBL (Eli Lilly Co., Indianapolis, IN); platinum compounds ± CDDP (Bristol Laboratories, Princeton, NJ) and CBDCA (Bristol Laboratories, Evansville, IN); topoisomerase II inhibitors ± VP-16 (Bristol Laboratories, Princeton, NJ); and taxanes ± TAX (Mead Johnson, Princeton, NJ). Following incubation for 72 h at 378C in a humidi®ed atmosphere containing 5% CO 2 , plates were washed with phosphate-buered NaCl solution (Dulbecco's PBS, Gibco BRL, Gaithersburg, MD) and stained with 0.5% crystal violet dye in methanol. Plates were then washed three times in water and allowed to dry. Sorenson's buer (0.025 M sodium citrate, 0.025 M citric acid in 50% ethanol) 0.1 ml was added to each well and the plates were analysed in an ELISA plate reader at 540 nm wavelength. Absorbance at this wavelength correlates closely to absolute cell number (Gillies et al., 1986; Reile et al., 1990; Flick and Giord, 1984) . The fraction of surviving cells relative to control were plotted against the log of drug concentration and the IC 50 was interpolated from the resulting sigmoidal curve using a 4-parameter curve ®t (SOFTmax; Molecular Devices Corporation, Menlo Park, CA).
In vivo drug sensitivity assays HER-2/neu or control vector-infected human breast (MCF7) or ovarian (2008) carcinoma cells were injected subcutaneously at 8610 6 ovarian cells and 0.5 ± 1.0610 7 breast cells/tumor in the mid-back region of 4 ± 6 week old, female CD-1 (nu/nu) mice (Charles River Laboratories, Wilmington, MA). Two tumors were established in each animal. The MCF7 breast carcinoma cells were injected with an equal volume of growth factor-reduced Matrigel (Collaborative Biomedical Products, Bedford, MA) to support tumor formation. Prior to cell injection, all mice were primed with 17b-estradiol (Innovative Research of America, Sarasota, FL) applied s.c. in a biodegradable carrier binder (1.7 mg estradiol/pellet) to promote tumor cell growth. Tumor volumes were calculated as the product of length, width, and depth, and were monitored twice weekly by serial micrometer measurements by a single observer. Six to seven animals were assigned to each treatment group such that the mean starting tumor volumes were the same in each group. Very large or very small tumors were excluded from the study prior to drug treatment. Statistical tests were performed (single-factor ANOVA) to assure uniformity in starting tumor volumes between treatment groups. Chemotherapeutic drugs or isovolumetric vehicle control solution were administered by i.p. injection. The dosage of chemotherapeutic agents tested were as follows: DOX (5 mg/kg), CDDP (5 mg/kg), 5-FU (100 mg/kg), TAX (15 mg/kg, day 0,1 and 2), VP-16 (25 mg/kg, day 0, 3 and 7) and TSPA (5 mg/kg, day 0, 1 and 2). In the MCF7 xenograft model all doses and dose schedules were repeated on day 14 of the experiment. These doses and dose schedules are based on independent dose ®nding experiments conducted in our laboratory and are near the MTD for this speci®c strain and weight of female athymic mice. Doses were based on individual animal weights determined immediately prior to injection. Drug treatment was initiated on day 5 post implantation for ovarian xenografts and day 12 post implantation for breast xenografts at which time measurable growing tumor nodules had formed. Mean tumor volumes of drug-treated relative to control-treated animals (T/C ratios) were calculated as a measure of response.
Statistical analysis
Dierences between in vitro dose-response curves for paired (NEO vs HER-2) cell lines were analysed using two-factor analysis of variance (ANOVA) of data points between the IC 20 and IC 80 . Dierences in tumor volumes following response to chemotherapy were compared using two-factor ANOVA. In addition, in the in vivo MCF7 breast xenograft model, dierences between MCF7/NEO and MCF7/HER-2 T/C ratios were compared using nonparametric methods (Mann-Whitney U test 
